Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis - 08/08/11
Abstract |
We report a patient with type 2 diabetes mellitus who, while treated with the antitumor necrosis factor-⍺ blocking agent etanercept for severe plaque psoriasis, experienced persistent hypoglycemia requiring the lowering and eventual elimination of his previous insulin regimen. After 20 months of therapy on etanercept, his plaque psoriasis markedly improved, whereas both his fasting blood sugars and glycosylated hemoglobin A1c decreased. Hypoglycemia can be a serious side effect of etanercept in patients already on antidiabetic medications known to cause hypoglycemia, such as sulfonylureas, meglitinides, and insulin. Thus, it is important for dermatologists treating patients with diabetes and antitumor necrosis factor-⍺ agents for psoriasis to be aware of potential hypoglycemia and to adjust antidiabetes therapy accordingly.
Le texte complet de cet article est disponible en PDF.Key words : cytokine, HbA1c, insulin, insulin resistance, TNF receptor
Abbreviations used : BMI, DM, HbA1c, IL, TNF, T2DM
Plan
Funding sources: None. |
|
Disclosure: Dr Bryer-Ash has received grant support as clinical investigator for Eli Lilly, Sanofi-Aventis, and Procter & Gamble. He is a speaker for Merck and received honorarium. He is on the advisory board for Novo Nordisk, and is shareholder for Amylin and Dexcom. Dr Cheung has no conflicts of interest to declare. |
|
Presented in part in abstract poster form at the American College of Physicians 2007 Southern California Regions I, II, and III Scientific Meeting in Indian Wells, CA, on October 20-21, 2007. |
Vol 60 - N° 6
P. 1032-1036 - juin 2009 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?